Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website https://www.gastrores.org

Short Communication

Volume 14, Number 3, June 2021, pages 190-193

Pre-Transplant Factors Influencing Rates of Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients

**Table 1.** Pre-transplant HCC Information for the Recurrent and Non-Recurrent Cohorts
HCC pre-transplant information	Non-recurrent (n = 123)	Recurrent (n = 9)	P value
Means (with standard deviation for continuous values, column percentages for ordinal/categorical variables) for each cohort represented, as well as P values for statistical significance between the cohorts. HCC: hepatocellular carcinoma; MELD: model for end-stage liver disease; AFP: alpha fetoprotein; TACE: transcatheter arterial chemoembolization.
Interval (days) between HCC diagnosis and transplant	503.5 ± 384.9	847.1 ± 635.8	0.015
Interval (days) between listing and transplant	224.9 ± 206.0	341.1 ± 190.3	0.103
MELD at diagnosis	11.9 ± 6.2	11.2 ± 4.9	0.745
AFP at diagnosis	220.6 ± 1,351.4	44.4 ± 105.2	0.698
Initial tumor number	1.4 ± 0.7	1.7 ± 0.7	0.312
Largest tumor measurement (cm)	2.9 ± 1.2	3.1 ± 1.4	0.576
Full Milan criteria	104 (87%)	7 (78%)	0.412
Treatment modality
Surgical resection	1 (1%)	1 (11%)	0.015
Ablation	34 (28%)	6 (67%)	0.014
Rounds of ablation	1.3 ± 0.8	1.5 ± 0.8	0.509
TACE	87 (71%)	7 (78%)	0.652
Rounds of TACE	1.4 ± 0.7	1.9 ± 0.9	0.072
Radiation	32 (26%)	5 (56%)	0.057
Rounds of radiation	1.1 ± 0.3	1.6 ± 0.5	0.011
Chemotherapy	2 (2%)	-	0.700
Total number of treatments pre-transplant	1.6 ± 1.0	3.6 ± 1.8	< 0.001
Lobe involved
Left	21 (17%)	1 (11%)	0.643
Right	97 (79%)	7 (78%)	0.939
Quadrate	15 (12%)	-	0.266
Caudate	5 (4%)	2 (22%)	0.019

Table 1. Pre-transplant HCC Information for the Recurrent and Non-Recurrent Cohorts

HCC pre-transplant information

Non-recurrent (n = 123)

Recurrent (n = 9)

P value

Means (with standard deviation for continuous values, column percentages for ordinal/categorical variables) for each cohort represented, as well as P values for statistical significance between the cohorts. HCC: hepatocellular carcinoma; MELD: model for end-stage liver disease; AFP: alpha fetoprotein; TACE: transcatheter arterial chemoembolization.

Interval (days) between HCC diagnosis and transplant

503.5 ± 384.9

847.1 ± 635.8

0.015

Interval (days) between listing and transplant

224.9 ± 206.0

341.1 ± 190.3

0.103

MELD at diagnosis

11.9 ± 6.2

11.2 ± 4.9

0.745

AFP at diagnosis

220.6 ± 1,351.4

44.4 ± 105.2

0.698

Initial tumor number

1.4 ± 0.7

1.7 ± 0.7

0.312

Largest tumor measurement (cm)

2.9 ± 1.2

3.1 ± 1.4

0.576

Full Milan criteria

104 (87%)

7 (78%)

0.412

Treatment modality

Surgical resection

1 (1%)

1 (11%)

0.015

Ablation

34 (28%)

6 (67%)

0.014

Rounds of ablation

1.3 ± 0.8

1.5 ± 0.8

0.509

TACE

87 (71%)

7 (78%)

0.652

Rounds of TACE

1.4 ± 0.7

1.9 ± 0.9

0.072

Radiation

32 (26%)

5 (56%)

0.057

Rounds of radiation

1.1 ± 0.3

1.6 ± 0.5

0.011

Chemotherapy

2 (2%)

0.700

Total number of treatments pre-transplant

1.6 ± 1.0

3.6 ± 1.8

< 0.001

Lobe involved

Left

21 (17%)

1 (11%)

0.643

Right

97 (79%)

7 (78%)

0.939

Quadrate

15 (12%)

0.266

Caudate

5 (4%)

2 (22%)

0.019

**Table 2.** Post-Transplant Outcomes and Complications for the Recurrent and Non-Recurrent Cohorts
Outcomes/complications	Non-recurrent (n = 123)	Recurrent (n = 9)	P value
Means (with percentages for ordinal/categorical variables) for each cohort represented, as well as P values for statistical significance between the cohorts. HAS: hepatic artery stenosis; HAT: hepatic artery thrombosis; DVT: deep venous thrombosis.
HAS	24 (20%)	4 (44%)	0.077
HAT	10 (8%)	-	0.371
Biliary leak	6 (5%)	-	0.496
Biliary stricture	21 (17%)	-	0.174
DVT	6 (5%)	2 (22%)	0.035
Reexploration	13 (11%)	1 (11%)	0.959
Graft rejection	19 (15%)	3 (33%)	0.165
Graft failure	12 (10%)	1 (11%)	0.895
Retransplant	5 (42%)	0 (%)	0.411
Death	19 (15%)	8 (89%)	< 0.001

Table 2. Post-Transplant Outcomes and Complications for the Recurrent and Non-Recurrent Cohorts

Outcomes/complications

Non-recurrent (n = 123)

Recurrent (n = 9)

P value

Means (with percentages for ordinal/categorical variables) for each cohort represented, as well as P values for statistical significance between the cohorts. HAS: hepatic artery stenosis; HAT: hepatic artery thrombosis; DVT: deep venous thrombosis.

HAS

24 (20%)

4 (44%)

0.077

HAT

10 (8%)

0.371

Biliary leak

6 (5%)

0.496

Biliary stricture

21 (17%)

0.174

DVT

6 (5%)

2 (22%)

0.035

Reexploration

13 (11%)

1 (11%)

0.959

Graft rejection

19 (15%)

3 (33%)

0.165

Graft failure

12 (10%)

1 (11%)

0.895

Retransplant

5 (42%)

0 (%)

0.411

Death

19 (15%)

8 (89%)

< 0.001